The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation
Open accessAbstract
CONTEXT: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. PATIENTS: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). INTERVENTION: The same daily dose of hydrocortisone was administered as OD dual-release or TID. MAIN OUTCOME MEASURE: We evaluated cortisol pharmacokinetics. RESULTS: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). CONCLUSION: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, whereas this dual-release hydrocortisone preparation was shown to slightly reduce blood pressure and HbA1c (104), such results may not always be desirable in patients with PAI.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“In men with CAH, gonadal and reproductive function are often impaired due to primary gonadal failure from TARTs and/or secondary gonadal failure due to suppressed hypothalamicpituitary-gonadal axis as a consequence of high adrenal androgen concentrations (378,437,438,625).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“The reported prevalence of TARTs in CAH ranges from 14% to 86% (437,634), with an average of 25% in adolescents, and 46% in men (378).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“TARTs are benign testicular tumors typically found in males with classic CAH (378,437).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Self-citationVgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7778 · Cited by 884 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
(1984) · Medical Entomology and Zoology · Cited by 741
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 2×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
Self-citationRossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346 · cited 2×
“This may be higher than reported in a previous cross-sectional survey (10) studying the frequency of adrenal crises only.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 7×
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citation
Cited by
Items 201–300 of 328
Monitoring adrenal insufficiency through salivary steroids: a pilot study
Tucci, L., Fanelli, F., Improta, I., Bissi, V., Lena, C., Galante, G., Mezzullo, M., Magagnoli, M., Lalumera, A. B., Colombin, G., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae037 · Cited by 6
Boesen, V. B., Christoffersen, T., Watt, T., Borresen, S. W., Klose, M., & Feldt‐Rasmussen, U. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019487 · Cited by 6
“Results will be submitted for publication in peer-reviewed journals. dIsCussIon Previous studies have shown improvements in fatigue and QoL in patients with primary adrenal insufficiency treated with Plenadren.”
InfluentialPark, J., Das, U., Didi, M., Ramakrishnan, R., Peak, M., Newland, P., & Blair, J. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0306-0 · Cited by 6
Ahmed, S. E. A. M., Soliman, A. T., Ramadan, M. A. E. F., Elawwa, A., Abugabal, A. M. S., Emam, M. H. A., & Sanctis, V. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i3.8732 · Cited by 14
“(21) found an obvious patient preference for once-daily regimens vs thricedaily regimens.”
BackgroundManagement of adrenal insufficiency during Ramadan fasting: a survey of physicians
Beshyah, S., Ali, K. F., & Saadi, H. (2020) · Endocrine Connections · doi:10.1530/ec-20-0314 · Cited by 6
“and Plenadren®) may allow for safer fasting practices [19,20].”
BackgroundCesana‐Nigro, N., Keshvari, S., Barclay, J. L., Sorbello, J., Upham, J. W., Benham, H., Anderson, S. T., Steiger, N., Prins, J. B., & Inder, W. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14108 · Cited by 6
Piazzola, C., Castinetti, F., von Fabeck, K., & Simon, N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf185 · Cited by 5
Clinical features, investigation, and management of Addison's disease
Dong, J., Hahner, S., Bancos, I., & Tomlinson, J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00393-6 · Cited by 5
L’insuffisance surrénalienne chez l’adulte
Jublanc, C., & Bruckert, É. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.02.007 · Cited by 6
Roshan, D., Yadav, J., Kumar, R., Malhi, P., Sharma, A., & Dayal, D. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.109269 · Cited by 6
“Parental education was associated with lower parent-reported scores in some domains, which can be explained by the fact that the more educated the parents, the more informed and worried they would be regarding the children’s future, reflecting in their perception of child’s QoL [2, 23, 24].”
BackgroundIncreased Resting-State Functional Connectivity in Patients With Autoimmune Addison Disease
Westeinde, A. V., Padilla, N., Fletcher‐Sandersjöö, S., Kämpe, O., Bensing, S., & Lajić, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad592 · Cited by 5
Extensive expertise in endocrinology: adrenal crisis in assisted reproduction and pregnancy
Feldt‐Rasmussen, U. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae005 · Cited by 7
Epidemiology, quality of life and complications of primary adrenal insufficiency: a review
Bensing, S., & Husebye, E. S. (2016) · Cited by 5
Glucocorticoid replacement therapies: past, present and future
Liew, S.-Y., Akker, S. A., Guasti, L., & Pittaway, J. F. H. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.08.011 · Cited by 7
Karunasena, N., Margetson, D. N., Neal, G., Whitaker, M. J., & Ross, R. J. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0948 · Cited by 5
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2019) · Endocrine · doi:10.1007/s12020-019-01956-3 · Cited by 6
Uncertainties in endocrine substitution therapy for central hypocortisolism
Swords, F. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00026-5 · Cited by 5
Espósito, D., Falorni, A., & Johannsson, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.886762 · Cited by 5
“A novel GC replacement treatment, dual-release oral hydrocortisone has been shown to provide a more circadian-based serum cortisol profile and has be associated to a better QoL as compared to conventional therapy (6).”
BackgroundSelf-citationAutoimmune Primary Adrenal Insufficiency: Understanding the Past, Present, and Future
Surani, A., & Carroll, T. B. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.008 · Cited by 8
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
“Johannsson et al. observed modest TG increases and reductions in HDL-C in most patients after 24 weeks, while TC decreased, sug - gesting potential long-term CV benefit [ 221].”
Diagnostik und Therapie der Nebenniereninsuffizienz
Harbeck, B., & Lehnert, H. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0721-2332 · Cited by 3
Frigerio, S., Carosi, G., Ferrante, E., Sala, E., Polledri, E., Fustinoni, S., Ambrosi, B., Chiodini, I., Mantovani, G., Morelli, V., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1093838 · Cited by 5
Wasmuth, A., van de Loo, I., Domberg, J., & Harbeck, B. (2025) · Endocrine · doi:10.1007/s12020-025-04192-0 · Cited by 4
Endocrine hypertension: What is new?
Koch, C. A. (2012) · Endocrinology Insights · doi:10.1016/s1646-3439(12)70010-x · Cited by 6
Reznik, Y. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.05.007 · Cited by 4
“Whether Duocort is safe on a once daily regimen was recently assessed in a 6-month and another 18-month study-period including the 64 patients with PAI previously mentioned [20].”
BackgroundMethodInfluentialMüller, M., Beiglböck, H., Fellinger, P., Winhofer, Y., Luger, A., Gschwandtner, M. E., Willfort‐Ehringer, A., Koppensteiner, R., Kautzky‐Willer, A., Krebs, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01309-2 · Cited by 4
Cardiovascular outcome in patients with adrenal insufficiency—a therapeutic dilemma
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2021) · Endocrine · doi:10.1007/s12020-020-02571-3 · Cited by 4
Endocrinological diagnosis and replacement therapy for hypopituitarism
Espósito, D., Johannsson, G., & Ragnarsson, Ó. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00027-5 · Cited by 7
Self-citationHarbeck, B., Kropp, P. A., & Kreitschmann‐Andermahr, I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1153595 · Cited by 5
Pulsatile Subcutaneous Hydrocortisone Replacement in Primary Adrenal Insufficiency
Šimůnková, K., Løvås, K., Methlie, P., Jovanovic, N., Bifulco, E., Brønstad, I., Lightman, S. L., Husebye, E. S., & Øksnes, M. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2092-5228 · Cited by 5
Jørgensen, N. T., Boesen, V. B., Borresen, S. W., Christoffersen, T., Jørgensen, N. R., Plomgaard, P., Christoffersen, C., Watt, T., Feldt‐Rasmussen, U., & Klose, M. (2024) · Endocrine · doi:10.1007/s12020-024-03711-9 · Cited by 4
“This is in line with other fi ndings of both saliva [36] and serum [16].”
BackgroundResultInfluentialDual-release Hydrocortisone in Addison’s Disease – A Review of the Literature
Giordano, R., Guaraldi, F., Berardelli, R., Karamouzis, I., Angelo, V. D., Zichi, C., Grottoli, S., Ghigo, E., & Arvat, E. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.01.75 · Cited by 5
Diagnosis and Management of Adrenal Insufficiency in Children and Adults
Llahana, S., Mitchelhill, I., Yeoh, P., & Quinkler, M. O. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_37 · Cited by 7
Improving glucocorticoid replacement in patients with adrenal insufficiency
Johannsson, G. (2016) · Endocrine · doi:10.1007/s12020-016-0929-2 · Cited by 4
Self-citationHypopituitarism—needs modern individualized treatment
Olsson, D. S., & Bengtsson, B. (2016) · Endocrine · doi:10.1007/s12020-016-1211-3 · Cited by 4
Multiple benefits from dual release hydrocortisone: a “hard” view from bones
Vassiliadi, D. A., & Tsagarakis, S. (2018) · Endocrine · doi:10.1007/s12020-018-1628-y · Cited by 4
Ross, R. J. M., Arlt, W., de la Perrière, A. B., Hirschberg, A. L., Juul, A., Merke, D. P., Newell-Price, J. D. C., Prete, A., Rees, A., Reisch, N., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15275 · Cited by 3
Kyle, C. J., Boyle, L. D., Nixon, M., Homer, N. Z. M., Simpson, J., Rutter, A., Ramage, L. E., Kelman, A., Freel, E. M., Andrew, R., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae144 · Cited by 4
Physiological Glucocorticoid Replacement in Adrenal Insufficiency: Does It Fix the Broken Clock?
Brown, M. R., & Matveyenko, A. V. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01245 · Cited by 3
Endocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00025-1 · Cited by 3
Han, M.-M., Zhang, J., Liu, Z., Xu, L., Bai, T., Xiang, C.-Y., Zhang, J., Lv, D.-Q., Liu, Y.-F., Wei, Y., et al. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i7.1112 · Cited by 3
Brooke, A. M., & Monson, J. P. (2013) · Medicine · doi:10.1016/j.mpmed.2013.06.006 · Cited by 4
Self-citationModified-release-Hydrocortison bei Glukokortikoidmangel
Nowotny, H. F., & Reisch, N. (2020) · Der Internist · doi:10.1007/s00108-020-00795-z · Cited by 2
Blanco, M. C., Vidal-Suárez, Á., & Martín-Portugués, A. B. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.10.010 · Cited by 3
New dual-release hydrocortisone tablet for adrenal insufficiency
Osório, J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.231 · Cited by 3
Endocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00024-x · Cited by 5
Burger‐Stritt, S., & Hahner, S. (2016) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-118276 · Cited by 5
Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency
Khoo, B. C. E. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30044-5 · Cited by 3
Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency
Choudhury, S., Tan, T., & Meeran, K. M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30045-7 · Cited by 3
Mazzeo, P., Tizianel, I., Sabbadin, C., Voltan, G., Antonelli, G., Ceccato, F., & Barbot, M. (2025) · Endocrine · doi:10.1007/s12020-025-04328-2 · Cited by 2
“In several studies of patients with primary and secondary AI receiving DR-HC was highlighted the importance of a more physiological cortisol rhythm in the amelioration of metabolic parameters [21, 25, 27, 31, 32].”
McQueen, J., Garner, T., Chantzichristos, D., Lennernäs, H., Espiard, S., Ragnarsson, Ó., Bergthorsdottir, R., Skrtic, S., Stevens, A., & Johannsson, G. (2026) · Scientific Reports · doi:10.1038/s41598-026-37816-0 · Cited by 3
“This study included a subpopulation of 18 patients who all underwent full 24-hour in-house pharmacokinetic sampling 15 .”
InfluentialSelf-citationKristensen, J. K., Brösamle, M., & van den Berg, B. (2021) · Endocrine · doi:10.1007/s12020-021-02653-w · Cited by 2
“New medications like slow-release and modified release hydrocortisone preparations and hydrocortisone tablets with lower dosages improve and better reflect the naturally occurring circadian endogenous release of glucocorticoids [2].”
BackgroundClinical Approach to Adrenal Insufficiency
Atiase, Y., Ampong, C., Baah, C. D., Yorke, E., & Akpalu, J. (2024) · Postgraduate Medical Journal of Ghana · doi:10.60014/pmjg.v13i1.329 · Cited by 2
“…immediate release hydrocortisone, it must be mentioned that recent modified release once daily forms with an outer shell of rapid release and an inner core of slow release has been shown to mimic the circadian rhythm with improved quality of life and metabolic effects of adrenal insufficiency 49 .”
Backgroundde Santana, L. B., Lima, T. A. D. S., Costa, A. R., Sandoval, L., de Souza, T. Y., da Mota, L. M. H., & Naves, L. A. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00394-8 · Cited by 2
“This aligns with the observation of symptom improvement in patients with adrenal insufficiency when using extended-release hydrocortisone, a presentation that provides a more physiological cortisol release [64].”
BackgroundApproach to the Child and Adolescent With Adrenal Insufficiency
Patti, G., Zucconi, A., Matarese, S., Tedesco, C., Panciroli, M., Napoli, F., Iorgi, N. D., & Maghnie, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae564 · Cited by 5
“This therapy approximates the physiological cortisol profile in the early part of the day and received European Medicines Agency approval in 2011 for the treatment of AI in adults (25, 26).”
Adrenal insufficiency and adrenal replacement therapy. Current status in Spain
Aulinas, A., Casanueva, F. F., Goñi, F., Monereo, S., Moreno, B., Pico, A. M., Puig‐Domingo, M., Salvador, J., Tinahones, F. J., & Webb, S. M. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.12.004 · Cited by 4
The ultradian rhythm of the glucocorticoid secretion and the time course of target gene regulation
Merkulov, V. M., Klimova, N. V., & Merkulova, T. I. (2016) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059716030084 · Cited by 4
“…to the optimization of the administration regimes of natural glucocorticoids reproducing not only the circadian rhythms of GCs secretion (Barbetta et al., 2005; Verma et al., 2010; Johannsson et al., 2012) but also ultradian ones (Rus sell and Lightman, 2014) are being developed at present.”
BackgroundPilli, T., Cardinale, S., Cantara, S., Dalmazio, G., Forleo, R., Capezzone, M., Bassi, C., Negrini, M., Ferracin, M., & Castagna, M. G. (2021) · Endocrine · doi:10.1007/s12020-020-02578-w · Cited by 2
Neues beim Adrenogenitalen Syndrom
Reisch, N. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-117270 · Cited by 3
“Bei Patienten mit primärer Nebennierenrindeninsuffizienz konnte gezeigt werden, dass Plenadren im Vergleich zu einem konventionellen HydrokortisonRegime eine Abnahme des Körpergewichts, des systolischen und diastolischen Blutdrucks und einen verbesserten Glukosemetabolismus zur Folge hat [2, 3].”
Brooke, A. M., & Monson, J. P. (2017) · Medicine · doi:10.1016/j.mpmed.2017.05.006 · Cited by 2
Self-citationSumerel, B., & Heaney, A. P. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch30 · Cited by 2
Improved salivary cortisol rhythm with dual-release hydrocortisone
Ceccato, F., Selmin, E., Sabbadin, C., Costa, M. D., Antonelli, G., Plebani, M., Barbot, M., Betterle, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.56.p56 · Cited by 2
Yukina, M. Y., Чернова, М. О., Nuralieva, N. F., Константиновна, Е. А., Troshina, E. A., Mel'nichenko, G. A., & Mokrysheva, N. G. (2020) · Obesity and metabolism · doi:10.14341/omet12700 · Cited by 2
Neue Hydrocortisonpräparate in der Therapie der Nebenniereninsuffizienz
Theiler‐Schwetz, V., Trummer, C., Pandis, M., & Pilz, S. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00156-1 · Cited by 1
“Hydrocortison in der äußeren Schicht der Tablette wird nach Ingestion morgens sofort freigesetzt, gefolgt von einer verzögerten Freisetzung von Hydrocortison aus dem Kern [8, 9].”
BackgroundFletcher‐Sandersjöö, S., Westeinde, A. V., Spelman, T. D., Hirvikosi, T., Lajić, S., & Bensing, S. (2025) · Clinical Endocrinology · doi:10.1111/cen.70028 · Cited by 2
“50 patients were treated with immediate ‐ release hydrocortisone (IR ‐ HC), and 14 with dual ‐ release hydrocortisone (DR ‐ HC; Plenadren®), with doses converted to IR ‐ HC equivalents using the formula: DR ‐ HC dose (mg)×0.806 [25].”
InfluentialEkman, B., Quinkler, M. O., Zhang, P., Isidori, A. M., Murray, R. D., Wahlberg, J., & on behalf of the EU-AIR investigators (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02657-7 · Cited by 2
Self-citationTraiter l’insuffisance surrénale : pour quels enjeux ? Par quels moyens thérapeutiques ?
Reznik, Y. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.003 · Cited by 2
Recent advancements in the drug treatment of endocrine diseases
Sam, A. H., & Meeran, K. M. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-2-170 · Cited by 1
Šimůnková, K., & Husebye, E. S. (2016) · Frontiers of hormone research · doi:10.1159/000443920 · Cited by 1
Glucocorticoid Replacement in Man
Russell, G. M., Løvås, K., & Lightman, S. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00078-x · Cited by 1
Turning back the clock on adrenal insufficiency
Johannsson, G. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30431-x · Cited by 1
Self-citationBetterle, C., & Zanchetta, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00042-3 · Cited by 1
Espiard, S., McQueen, J., Sherlock, M., Ragnarsson, Ó., Bergthorsdottir, R., Burman, P., Dahlqvist, P. M., Ekman, B., Engstrom, B. E., Skrtic, S., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.8.5 · Cited by 1
Self-citationAllosso, F., Dalakas, K., Bergthorsdottir, R., Chantzichristos, D., Hessman, E., Nwaru, B. I., Bobbio, E., Pasquali, D., Johannsson, G., & Espósito, D. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076582 · Cited by 1
Self-citationCognitive Assessment in Adults With Adrenal Cortisol Insufficiency: Challenges and Opportunities
Ben-Shlomo, A., Koh, M., Kremen, S. A., & Wertheimer, J. C. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf029 · Cited by 4
Dual-release Hydrocortisone in Addison’s Disease—A Review of the Literature
Giordano, R., Guaraldi, F., Berardelli, R., Karamouzis, I., Angelo, V. D., Zichi, C., Grottoli, S., Ghigo, E., & Arvat, E. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.177 · Cited by 1
Wild, C. M., Stieg, M. R., Stalla, G. K., Jung‐Sievers, C., Auer, M. K., & Athanasoulia-Kaspar, A. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044197 · Cited by 2
Glucocorticoids - outcome in patients with glucocorticoid deficiency and Cushing's syndrome
Ragnarsson, Ó. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Secondary Adrenal Insufficiency
Else, T., & Auchus, R. J. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch4 · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
Hypopituitarism, Causes, Diagnosis, Management and Mortality
Fountas, A., & Karavitaki, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64277-0 · Cited by 1
Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency – Authors' reply
Isidori, A. M., Hasenmajer, V., & Venneri, M. A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30040-8 · Cited by 1
Øksnes, M., & Husebye, E. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00220-x · Cited by 1
Insuficiencia suprarrenal, tratamiento sustitutivo y hueso
Reyes‐García, R., & Martín, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-503-5.00009-5
Quality of Life Rated Too Negatively
Oelkers, W. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0224a
Mortality and morbidity in patients with Addison's disease
Bergthorsdottir, R. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Self-citationEndocrine Consequences: Diagnostic Workout and Treatment
Giavoli, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-22297-4_7
C URRENT OPINION Current and emerging therapies for Addison's disease
Napier, C., & Pearce, S. H. S. (2014)
Fontanella, A., Nardi, R., Masina, M., & Uomo, G. (2017) · Italian Journal of Medicine · doi:10.4081/itjm.q.2017.7
Giordano, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13748
Salah, D. B., Charfi, N., Elleuch, M., Kacem, F. H., Rekik, N., Mnif, M., Mnif, F., & Abid, M. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.251.12546 · Cited by 1
“Giordano dans son étude, a trouvé un profil correct chez les addisoniens et les témoins [11].”
BackgroundInfluentialInsuffisance surrénalienne secondaire : actualités diagnostiques et thérapeutiques
Vinolas, H., Lombès, M., & Tabarin, A. (2019) · Annales d Endocrinologie · doi:10.1016/s0003-4266(19)30111-8
Anterior Pituitary and Pars Intermedia Space
Romanò, N., & Shipston, M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00008-0 · Cited by 3
de Miranda, M. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-29102020-162042
Fixing the broken clock in adrenal disorders: Focus on glucocorticoids and chronotherapy
Minnetti, M., Hasenmajer, V., Pofi, R., Venneri, M. A., Alexandraki, K. I., & Isidori, A. M. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.8.19
Terapia sostitutiva corticosteroidea alla luce delle nuove proposte farmacologiche (Plenadren®)
Cappiello, V., Giannelli, J., & Giordano, R. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00860-1
Principles of Hormone Replacement
Ross, R. J. M. (2022) · doi:10.1093/med/9780198870197.003.0012
Hypopituitarism: Replacement of Adrenal, Thyroid, and Gonadal Axes
Levy, M. J., Bhake, R. C., & Reddy, N. (2022) · doi:10.1093/med/9780198870197.003.0021
Betterle, C., Presotto, F., & Zanchetta, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00042-7
Metadata
- Authors
- Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., Wahlberg, J., Biller, B. M. K., Monson, J. P., Stewart, P. M., Lennernäs, H., & Skrtic, S.
- Affiliations
- University of Gothenburg (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
- Linköping University (SE)
- Uppsala University Hospital (SE)
- Harvard University (US)
- St Bartholomew's Hospital (GB)
- University of Birmingham (GB)
- Uppsala University (SE)
- Corresponding author
- Johannsson, G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 473-481
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2108430953
- Semantic Scholar
- 89ffc7ce5ac189e54ea0a893bc1b71924fce41b3
- Cited by
- 329
- References
- 30
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 22 · 2018: 34 · 2017: 25 · 2016: 33 · 2015: 14 · 2014: 33 · 2013: 20 · 2012: 10
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- green
- lup.lub.lu.se
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- adrenal insufficiency, cortisol, once-daily dosing, HbA1c, glucose metabolism, diabetes mellitus, blood pressure, body weight, sustained-release tablets
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Chemistry, Pharmaceutical, Delayed-Action Preparations, Female, Humans, Hydrocortisone, Male, Middle Aged, Time Factors, Treatment Outcome, Cross-Over Studies, Area Under Curve, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.